StemPar Sciences is dedicated to the translation of scientific advances into new medicines to treat cancer.
Company Overview
StemPar is developing a pipeline of powerful, first-in-class cancer drugs that attack solid tumors by simultaneously disrupting their source of energy and defensive ability to hijack the body's DNA-repair mechanism to regenerate when under assault. The scientific premise of this so-called cancer metabolism strategy has been studied for generations--and earned the scientist who discovered it a Nobel Prize--but it is only recently that scientists figured out how to crack the code of cancer metabolism sufficiently to build a commercially viable drug development effort around it. Their scientists are at the forefront of this effort and thier leadership team has long been at the forefront of transforming breakthrough scientific discoveries into life-saving medicines.
Our Technology - SPS-201
Our lead program comprises a novel therapeutic agent, SPS-201, which targets NQO1, an enzyme frequently expressed at high levels in tumors. SPS-201 redirects NQO1 from its physiological role in quinone detoxification to that of a "futile redox cycle" and potently depletes energy reserves of cancer cells by reducing NAD(P)H/ATP levels, while concomitantly generating toxic levels of reactive oxygen species (ROS).
Connect With StemPar Sciences
Want to learn more about StemPar Sciences or have a question about our approach? Use the contact form and let’s start a conversation.